Aurobindo Pharma announces the completion of a share transfer involving its subsidiary, CuraTeQ Biologics s.r.o. The shares, previously held by Helix Healthcare B.V., have been transferred to Curateq Biologics B.V., another wholly-owned subsidiary. This transfer was completed by November 30, 2025, after receiving confirmation from Czech Republic authorities on September 30, 2025. Post-transfer, CuraTeQ Biologics s.r.o. is now a wholly-owned subsidiary of Curateq Biologics B.V.
Share Transfer Completion
Aurobindo Pharma has announced the successful completion of a share transfer involving its subsidiary, CuraTeQ Biologics s.r.o. The company previously informed about a binding agreement for this transfer in letters dated July 30, 2025, August 29, 2025, and September 26, 2025.
Details of the Transfer
The share transfer involved the entire shares of CuraTeQ Biologics s.r.o., previously held by Helix Healthcare B.V. The shares have now been transferred to Curateq Biologics B.V., another wholly owned subsidiary of Aurobindo Pharma. The transfer was officially completed by November 30, 2025.
Regulatory Confirmation
Aurobindo Pharma received confirmation from the local authority of the Czech Republic on September 30, 2025, regarding the share transfer.
Post-Transfer Status
Following the successful completion of the share transfer, CuraTeQ Biologics s.r.o. has ceased to be a wholly-owned subsidiary of Helix Healthcare B.V. and is now a wholly-owned subsidiary of Curateq Biologics B.V.
Source: BSE
